Metastatic Prostate Cancer Treatment segmentation by type distinguishes five therapeutic classes that together define the market’s product mix. Chemotherapy, anchored by docetaxel and cabazitaxel, remains the primary cytotoxic option and contributes roughly 30 % of total spend, driven by its use in later‑line CRPC where price points are moderate but cycles are repeated. Immunotherapy, represented chiefly by checkpoint inhibitors such as pembrolizumab, occupies a niche of about 10 % due to limited FDA‑approved indications and high acquisition cost. Targeted therapy, including PARP inhibitors (olaparib, rucaparib) and AKT inhibitors, accounts for approximately 25 % as precision‑medicine uptake rises in biomarker‑selected populations. Radiopharmaceuticals, exemplified by radium‑223 and lutetium‑177‑PSMA‑617, generate close to 20 % of revenue, reflecting their dual role in pain palliation and disease control for bone‑dominant metastases. Hormone therapy, covering next‑generation androgen receptor antagonists (enzalutamide, apalutamide, darolutamide) and androgen synthesis inhibitors (abiraterone), retains the largest share at roughly 35 %, supported by long‑term dosing and broad label use. The share of each type is a function of clinical efficacy, reimbursement environment, and patient‑level pathways, forming a clear market taxonomy for Metastatic Prostate Cancer Treatment segmentation.
